Van Lanschot Kempen Investment Management N.V. Has $15.52 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Van Lanschot Kempen Investment Management N.V. lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 35.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 78,981 shares of the medical research company’s stock after selling 44,132 shares during the period. Van Lanschot Kempen Investment Management N.V.’s holdings in IQVIA were worth $15,521,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IQV. TD Waterhouse Canada Inc. lifted its position in shares of IQVIA by 1.9% in the 4th quarter. TD Waterhouse Canada Inc. now owns 18,167 shares of the medical research company’s stock worth $3,572,000 after purchasing an additional 330 shares during the period. Tower Research Capital LLC TRC raised its position in shares of IQVIA by 76.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,707 shares of the medical research company’s stock worth $2,104,000 after purchasing an additional 4,632 shares during the period. Thematics Asset Management acquired a new position in shares of IQVIA during the fourth quarter valued at about $76,000. Trajan Wealth LLC grew its holdings in IQVIA by 4.1% during the fourth quarter. Trajan Wealth LLC now owns 80,202 shares of the medical research company’s stock worth $15,760,000 after buying an additional 3,179 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in IQVIA by 1.3% in the 4th quarter. MetLife Investment Management LLC now owns 46,670 shares of the medical research company’s stock valued at $9,171,000 after buying an additional 588 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $141.38 on Tuesday. The stock has a 50-day moving average of $175.30 and a 200 day moving average of $195.79. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The stock has a market capitalization of $24.93 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 1.99 and a beta of 1.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Barclays restated an “equal weight” rating and set a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Finally, Robert W. Baird decreased their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.